<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119496</url>
  </required_header>
  <id_info>
    <org_study_id>RES104033</org_study_id>
    <secondary_id>2004-004247-22 EUDRACT</secondary_id>
    <nct_id>NCT00119496</nct_id>
  </id_info>
  <brief_title>Rosiglitazone Versus Theophylline in Asthmatic Smokers</brief_title>
  <official_title>A Clinical Study to Investigate the Effect of Rosiglitazone, Theophylline and Inhaled Corticosteroid, Inflammation and Pulmonary Function in Asthmatic Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chest, Heart and Stroke Association Scotland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chief Scientist Office of the Scottish Government</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Glasgow</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthmatic smokers display a blunted response to both inhaled and oral corticosteroid&#xD;
      treatments and are at increased risk for exacerbations and near fatal asthma. The prevalence&#xD;
      of smoking in asthmatics runs between 20-30%. Therefore, new, more efficacious treatments are&#xD;
      required.&#xD;
&#xD;
      Recent work has demonstrated a mechanism which may explain steroid resistance. A commonly&#xD;
      used drug called theophylline can reverse this steroid resistance in laboratory studies.&#xD;
      Another commonly used drug, rosiglitazone can reverse smoking induced lung inflammation in&#xD;
      laboratory studies.&#xD;
&#xD;
      The investigators aim to study the effects of these drugs on smoking asthmatics' lung&#xD;
      function and other parameters including quality of life and asthma control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Smoking asthmatics have chronic pulmonary inflammation that is relatively steroid resistant.&#xD;
      PPAR agonists (of which rosiglitazone is one example) have been shown to reduce several&#xD;
      markers of inflammation in humans and in smoking animal models.&#xD;
&#xD;
      This clinical study will use smoking asthmatics as a human model of smoke-induced&#xD;
      steroid-insensitive airway inflammation to evaluate both efficacy of rosiglitazone as an&#xD;
      anti-inflammatory drug as well as the effect of low doses of theophylline on the response to&#xD;
      low-dose inhaled corticosteroid (LD ICS).&#xD;
&#xD;
      Mild or moderate (as per GINA guidelines) persistent-asthmatic smokers will be randomised&#xD;
      into this study after a 4-week washout period during which they will be withdrawn from&#xD;
      inhaled corticosteroids (ICS). Subjects will then receive one of four treatments for 28 days:&#xD;
      rosiglitazone, LD ICS, theophylline, or LD ICS plus theophylline.&#xD;
&#xD;
      The effects of rosiglitazone and LD ICS on pulmonary function will be compared as a primary&#xD;
      objective. In addition, effects of theophylline plus LD ICS will be compared against&#xD;
      theophylline and LD ICS separately. Both pulmonary anti-inflammatory and systemic&#xD;
      anti-inflammatory activity will also be investigated.&#xD;
&#xD;
      Subjects will have baseline assessments of pulmonary function, biomarkers of systemic&#xD;
      inflammation, sputum, exhaled breath biomarkers, asthma control questionnaires and safety&#xD;
      parameters. Following 28 days of treatment, these parameters will all be reassessed in all&#xD;
      subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of pre-bronchodilator (FEV1) at 28 days between rosiglitazone and LD ICS treatment groups.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rosiglitazone vs LD ICS on other endpoints of pulmonary function in smoking asthmatics.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Theophylline plus LD ICS vs LD ICS on pulmonary function in smoking asthmatics.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Theophylline plus LD ICS vs theophylline on pulmonary function in smoking asthmatics.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of rosiglitazone, LD ICS, theophylline and theophylline plus LD ICS in smoking asthmatics.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects in smoking asthmatics of rosiglitazone, LD ICS, theophylline and theophylline plus LD ICS on asthma control using the ACQ (Juniper et al, 1999).</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaled beclomethasone (400mcg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosiglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral theophylline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral theophylline and inhaled beclomethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone</intervention_name>
    <description>oral tablet, 4mg bd for 4 weeks</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Rosiglitazone Maleate, Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>theophylline</intervention_name>
    <description>Oral theophylline, 200mg bd</description>
    <arm_group_label>Arm3</arm_group_label>
    <other_name>uniphyllin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beclomethasone</intervention_name>
    <description>inhaled beclomethasone, 200mcg bd</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Qvar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled beclomethasone and oral theophylline</intervention_name>
    <description>inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)</description>
    <arm_group_label>Arm 4</arm_group_label>
    <other_name>Qvar and uniphyllin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females between 18 and 60 years of age (inclusive).&#xD;
&#xD;
          -  Clinical diagnosis of mild or moderate persistent asthma in accordance with the Global&#xD;
             Initiative for Asthma (GINA) criteria&#xD;
&#xD;
          -  Have had a history of asthma for a minimum of 6 months prior to entry into the study&#xD;
&#xD;
          -  Subjects must be current cigarette smokers with a minimum five-pack-year smoking&#xD;
             history&#xD;
&#xD;
          -  Baseline FEV1 that is greater than 50% predicted; and reversibility of 12% or more at&#xD;
             screening, washout or randomisation.&#xD;
&#xD;
          -  Capable of providing signed written informed consent and complying with all the&#xD;
             specified study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Asthma exacerbation or a respiratory tract infection within four weeks of screening.&#xD;
&#xD;
          -  Type 1 or type 2 diabetes mellitus.&#xD;
&#xD;
          -  Women who are lactating, pregnant, or planning to become pregnant.&#xD;
&#xD;
          -  Clinically significant renal or hepatic laboratory values (e.g. AST/ALT/total&#xD;
             bilirubin/AP &gt; 2.5 times normal values).&#xD;
&#xD;
          -  Anaemia (&lt; 11 g/dL for males or &lt; 10 g/dL for females)&#xD;
&#xD;
          -  Contraindications to treatment as outlined in any of the product labels&#xD;
&#xD;
          -  Prior history of severe oedema or serious fluid related event (e.g., heart failure)&#xD;
             associated with any TZD&#xD;
&#xD;
          -  The subject has a history of significant hypersensitivity to study drugs&#xD;
&#xD;
          -  Presence of unstable or severe angina or congestive heart failure (NYHA class III/IV)&#xD;
             or evidence or history of known congestive heart failure (NYHA class I-IV) or an&#xD;
             abnormal electrocardiogram (ECG), as determined by the Investigator, or subjects who&#xD;
             have had new cardiac events (such as MI, new CHF, PTCA, CABG) within 6 months of&#xD;
             screening.&#xD;
&#xD;
          -  History or suspicion of current drug abuse or alcohol abuse within the last 6 months.&#xD;
&#xD;
          -  History suggestive of active infection or non-asthma lung pathology&#xD;
&#xD;
          -  Clinically significant renal disease, metabolic syndrome, cirrhosis (Child-Pugh Class&#xD;
             B/C), hypertension or any other clinically significant cardiovascular, neurological,&#xD;
             endocrine, or haematological abnormalities that are uncontrolled on permitted therapy.&#xD;
&#xD;
          -  Risk factors for human immunodeficiency virus (HIV), hepatitis B or hepatitis C&#xD;
             infection at Screening (Visit 1)&#xD;
&#xD;
          -  Subjects who are morbidly obese, defined as having a body mass index (BMI) &gt; 40 kg/m2&#xD;
&#xD;
          -  Unable to perform spirometry&#xD;
&#xD;
          -  Subjects who require treatment with any of the following asthma medications from&#xD;
             Screening (Visit 1) until study completion:&#xD;
&#xD;
               -  Inhaled cromolyn sodium or nedocromil;&#xD;
&#xD;
               -  Ipratropium bromide;&#xD;
&#xD;
               -  Xanthines (theophylline preparations);&#xD;
&#xD;
               -  Leukotriene modifiers;&#xD;
&#xD;
               -  Long-acting inhaled beta2-agonists (salmeterol, formoterol);&#xD;
&#xD;
               -  Oral beta2-agonists.&#xD;
&#xD;
          -  Treatment with oral, intravenous or intra-articular corticosteroids within 6 weeks of&#xD;
             Screening or thereafter.&#xD;
&#xD;
          -  Subjects who have been taking in excess of 1000 Î¼g daily of beclomethasone (or&#xD;
             equivalent) within 6 weeks of Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil C Thomson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asthma Research Group, Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.gla.ac.uk/departments/immunology/respiratorymedicine/</url>
    <description>Asthma Research Unit website</description>
  </link>
  <reference>
    <citation>Spears M, McSharry C, Thomson NC. Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy. 2006 Dec;36(12):1494-504. Review.</citation>
    <PMID>17177672</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>July 1, 2005</study_first_submitted>
  <study_first_submitted_qc>July 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2005</study_first_posted>
  <last_update_submitted>January 26, 2010</last_update_submitted>
  <last_update_submitted_qc>January 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2010</last_update_posted>
  <keyword>Corticosteroid</keyword>
  <keyword>Rosiglitazone</keyword>
  <keyword>Theophylline</keyword>
  <keyword>Beclomethasone</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Asthma</keyword>
  <keyword>Smoking</keyword>
  <keyword>Pulmonary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

